Cargando…
Empowering Clinical Diagnostics with Mass Spectrometry
[Image: see text] The unmet need for highly accurate methods of disease diagnosis poses new challenges for developments in laboratory medicine. Advances in mass spectrometry (MS)-based disease biomarker discoveries are continuously expanding the clinical diagnostic landscape. Although a number of MS...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016904/ https://www.ncbi.nlm.nih.gov/pubmed/32064364 http://dx.doi.org/10.1021/acsomega.9b03764 |
_version_ | 1783497082689028096 |
---|---|
author | Banerjee, Shibdas |
author_facet | Banerjee, Shibdas |
author_sort | Banerjee, Shibdas |
collection | PubMed |
description | [Image: see text] The unmet need for highly accurate methods of disease diagnosis poses new challenges for developments in laboratory medicine. Advances in mass spectrometry (MS)-based disease biomarker discoveries are continuously expanding the clinical diagnostic landscape. Although a number of MS-based in vitro diagnostics are already adopted in routine clinical practices, more are expected to undergo transition from bench to bedside in the near future. The ultrahigh sensitivity, specificity, and low turnaround time in molecular detection by MS make this technology highly powerful in disease detection and therapy monitoring. This mini-review highlights how MS has created a new paradigm in clinical diagnosis, which is growing in importance for public health. |
format | Online Article Text |
id | pubmed-7016904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-70169042020-02-14 Empowering Clinical Diagnostics with Mass Spectrometry Banerjee, Shibdas ACS Omega [Image: see text] The unmet need for highly accurate methods of disease diagnosis poses new challenges for developments in laboratory medicine. Advances in mass spectrometry (MS)-based disease biomarker discoveries are continuously expanding the clinical diagnostic landscape. Although a number of MS-based in vitro diagnostics are already adopted in routine clinical practices, more are expected to undergo transition from bench to bedside in the near future. The ultrahigh sensitivity, specificity, and low turnaround time in molecular detection by MS make this technology highly powerful in disease detection and therapy monitoring. This mini-review highlights how MS has created a new paradigm in clinical diagnosis, which is growing in importance for public health. American Chemical Society 2020-01-30 /pmc/articles/PMC7016904/ /pubmed/32064364 http://dx.doi.org/10.1021/acsomega.9b03764 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Banerjee, Shibdas Empowering Clinical Diagnostics with Mass Spectrometry |
title | Empowering Clinical Diagnostics with Mass Spectrometry |
title_full | Empowering Clinical Diagnostics with Mass Spectrometry |
title_fullStr | Empowering Clinical Diagnostics with Mass Spectrometry |
title_full_unstemmed | Empowering Clinical Diagnostics with Mass Spectrometry |
title_short | Empowering Clinical Diagnostics with Mass Spectrometry |
title_sort | empowering clinical diagnostics with mass spectrometry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016904/ https://www.ncbi.nlm.nih.gov/pubmed/32064364 http://dx.doi.org/10.1021/acsomega.9b03764 |
work_keys_str_mv | AT banerjeeshibdas empoweringclinicaldiagnosticswithmassspectrometry |